Health Care • Biotechnology: Pharmaceutical Preparations
$307.02 ▼ -15.73
(-4.87%)
MKT CAP: $6.43B • VOL: 265.5K
52W L $176 52W H $327
LGND // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $268.1M | $167.1M | $131.3M |
| YoY Revenue Growth % | +60.4% | +27.3% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $41.0M | -$22.6M | $11.9M |
| Operating Margin % | 15.3% | -13.5% | 9.1% |
| Net Income (GAAP) | $124.5M | -$4.0M | $52.2M |
| EBITDA (Normalized) | $41.4M | -$21.1M | $16.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $49.4M | $97.0M | $49.6M |
| Capital Expenditures (CapEx) | $452.0K | $1.8M | $5.9M |
| Free Cash Flow (FCF) | $48.9M | $95.2M | $43.7M |
| FCF Margin % | 18.2% | 57.0% | 33.3% |
| Return on Invested Capital (ROIC %) | 3.0% | -2.2% | 0.4% |
| Cash & Short-Term Equivalents | $174.9M | $72.3M | — |
| Total Debt (Short + Long Term) | $244.5M | $50.1M | $814.2M |
| Total Stockholders' Equity | $1.02B | $830.4M | $1.67B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR LGND.